FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/New Trial Launches to Evaluate LY3457263 for Type 2 Diabetes Patients on Semaglutide or Tirzepatide
연구 도서관으로 돌아가기

New Trial Launches to Evaluate LY3457263 for Type 2 Diabetes Patients on Semaglutide or Tirzepatide

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

New Trial Launches to Evaluate LY3457263 for Type 2 Diabetes Patients on Semaglutide or Tirzepatide

Eli Lilly and Company has initiated a new clinical trial aimed at evaluating the effectiveness of LY3457263, a novel peptide compound, in treating type 2 diabetes patients who are not achieving their HbA1c targets while using semaglutide or tirzepatide. This Phase 2 study promises to provide valuable insights into the potential benefits and safety profile of this experimental therapy for those with uncontrolled blood sugar levels despite current treatment regimens.

Background

Type 2 diabetes affects millions of people worldwide, with many individuals struggling to maintain optimal glycemic control even after being prescribed GLP-1 receptor agonists like semaglutide or tirzepatide. These medications are part of a broader class of peptide therapies that have shown promise in managing blood sugar levels through various mechanisms, including appetite suppression and improved insulin secretion.

However, for some patients, these treatments alone may not be sufficient to achieve the recommended HbA1c levels below 7%. This underscores the need for novel therapeutic options that can enhance glycemic control further. LY3457263 is a new peptide being developed by Eli Lilly and Company with the potential to offer additional benefits over existing GLP-1 receptor agonists.

Key Details

The current study, which began recruiting participants in May 2026, will compare LY3457263 against a placebo in patients with type 2 diabetes who are already on stable doses of semaglutide or tirzepatide but have not yet reached their HbA1c targets. The primary outcome measure is the change in hemoglobin A1c (HbA1c) levels over nine months, providing a clear indication of how effectively LY3457263 can enhance glycemic control compared to no intervention.

Participants will be closely monitored throughout the study period to assess safety and tolerability. Other secondary endpoints may include changes in body weight, blood pressure, and lipid profiles, reflecting the multifaceted benefits that this new peptide therapy might offer beyond just glucose regulation.

Key Takeaways

  • LY3457263 shows promise as an adjunctive treatment for type 2 diabetes patients currently using semaglutide or tirzepatide but struggling to achieve glycemic targets.
  • The study aims to provide critical data on efficacy and safety, which are crucial considerations before any new peptide therapy can be approved by regulatory bodies like the FDA.
  • Participants will be evaluated over a nine-month period, allowing for comprehensive analysis of long-term outcomes associated with LY3457263 treatment.
  • The research could pave the way for improved therapeutic options in managing type 2 diabetes, addressing unmet needs within this patient population.

What This Means

For the peptide community, this trial represents a significant step forward in exploring new avenues to enhance glycemic control among patients with type 2 diabetes. As more clinical data becomes available, it will help researchers and clinicians better understand the potential role of LY3457263 in combination therapy settings.

Moreover, successful outcomes from this study could lead to broader acceptance of peptide-based therapies for treating diabetes beyond current GLP-1 receptor agonists. This research not only advances our understanding of type 2 diabetes management but also underscores the continuous evolution of peptide treatments within the medical field.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.